GNRHR and polycystic ovary syndrome: After the addition of cetrorelix, GnRHR-AAb activity significantly decreased in the PCOS group from a 3.66-fold to 3.17-fold increase over buffer baseline (p < 0.0001), while in the control group, it remained largely unchanged.